AAP
TLX

Arax Advisory Partners’s Telix Pharmaceuticals TLX Stock Holding History

Arax Advisory Partners’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.86K Sell
125
-958
-88% -$7.3K ﹤0.01% 2448
2025
Q4 		$8.12K Buy
1,083
+53
+5% +$510 ﹤0.01% 2584
2025
Q3 		$9.86K Hold
1,030
– – ﹤0.01% 2608
2025
Q2 		$16.6K Buy
+1,030
New +$17.3K ﹤0.01% 1731

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Arax Advisory Partners's TLX Position: Q1 2026 in Review

Arax Advisory Partners reduced its Telix Pharmaceuticals (TLX) stake by 88% in Q1 2026, selling an estimated $7.3K and leaving 125 shares worth $9.86K. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Arax Advisory Partners first reported a position in TLX in Q2 2025 and has held it in 4 quarters since. The position peaked at $16.6K in Q2 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • Arax Advisory Partners held 125 shares of Telix Pharmaceuticals worth $9.86K as of Q1 2026.
  • Arax Advisory Partners sold 958 Telix Pharmaceuticals shares in Q1 2026, an estimated $7.3K.
  • Telix Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2448 holding.
  • Arax Advisory Partners first reported a position in Telix Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Telix Pharmaceuticals position peaked at $16.6K in Q2 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.